Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial

Höglinger, Günter U., Huppertz, Hans‐Jürgen, Wagenpfeil, Stefan, Andrés, María V, Belloch, Vincente, León, Teresa, del Ser, Teodoro, for the TAUROS MRI Investigators·2014·Movement Disorders
DOI 10.1002/mds.25815

Cited by (163)

Items 101–163 of 163

  1. Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
    Davide Vito Moretti, Giuliano Gb. Binetti, Orazio Oz. Zanetti, Giovanni Battista Frisoni · 2014 · Frontiers in Neurology
  2. Tau Diagnostics and Clinical Studies
    Illana Gozes, Günter U. Höglinger, James P. Quinn, Nigel M. Hooper, Kina Höglund · 2017 · Journal of Molecular Neuroscience
  3. Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD
    Jigar Vyas, Nensi Raytthatha, Bhupendra Gopalbhai Prajapati · 2024 · Elsevier eBooks
  4. Alzheimer's disease research in Ibero America
    Heather M. Snyder, María del Carmen Cárdenas‐Aguayo, Alejandra del C. Alonso, Lisa J. Bain, Khalid Iqbal, María C. Carrillo · 2016 · Alzheimer s & Dementia
  5. Development of a cognitive composite for measuring change in progressive supranuclear palsy
    Judith Jaeger, Lili Yang, Yumeng Li, Carmen Castrillo‐Viguera, Samantha Budd Haeberlein, Tien Dam, John T. O'Gorman · 2021 · Parkinsonism & Related Disorders
  6. Dynamics of microtubules and their associated proteins
    Eduardo Elias Benarroch · 2016 · Neurology
  7. 1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism
    Stephanie Mangesius, Florian Krismer, Elke Ruth Gizewski, Christoph Felix Müller, Anna Hussl, Michael Schocke, Christoph Scherfler, Werner H Poewe, Klaus Seppi · 2016 · Movement Disorders
  8. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study
    Davide Vito Moretti, Giuliano Gb. Binetti, Orazio Oz. Zanetti, Giovanni Battista Frisoni · 2014 · Neuropharmacology
  9. Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
    Tridente, Giuseppe, Jana, Ankit, Nath, Arnab, Ashraf, Ghulam Md · 2023 · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders
  10. Disease-modifying vs symptomatic treatments: Splitting over lumping
    Kevin R. Duque, Joaquín A. Vizcarra, Emily J. Hill, Alberto Javier Espay · 2023 · Handbook of clinical neurology
  11. The regenerative potential of Tideglusib and CHIR99021 small molecules as potent odontogenic differentiation enhancers of human dental pulp stem cells
    Samer Hanna, Ghada Nour Eldeen, Ruth Pérez Alfayate, Riham Mohammed Aly · 2023 · Clinical Oral Investigations
  12. Robust and predictive 3D-QSAR models for predicting the activities of novel oxadiazole derivatives as multifunctional anti-Alzheimer agents
    Yekai Sun, Zirou Zhang, Menghao Wen, Fangfang Wang, Xiuling Li, Wei Yang, Bo Zhou · 2024 · RSC Advances
  13. Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy
    Brent Bluett, Irene Litvan · 2015 · Expert Opinion on Orphan Drugs
  14. Tauopathien
    Gábor Géza Kovács, Gesine Respondek, Thilo van Eimeren, E Holler, Johannes Levin, Ulrich Müller, Sigrid C. Schwarz, Thomas W. Rösler, Kerstin Schweyer, Günter U. Höglinger · 2018 · Der Nervenarzt
  15. Disease‐Modifying Treatments for Progressive Supranuclear Palsy
    María Stamelou, Adam L. Boxer · 2015 · Movement Disorders Clinical Practice
  16. GSK-3 Inhibitors: From the Brain to the Retina and Back Again
    Alonso Sánchez-Cruz, Ana Martı́nez, Enrique J. de la Rosa, Catalina Hernández‐Sánchez · 2019 · Advances in experimental medicine and biology
  17. Multiparametric MRI-based biomarkers in the non-fluent and semantic variants of primary progressive aphasia
    Marco Michelutti, Hans‐Jürgen Huppertz, Heiko Volkmann, Sarah Anderl‐Straub, Daniele Urso, Benedetta Tafuri, Salvatore Lo Nigro, Paolo Manganotti, Leonie Werner, Jolina Lombardi et al. · 2025 · Journal of Neurology
  18. Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders
    Fei Tang, Junfen Wei, Ma-Li Wong, Peng Lei · 2025 · Genomic psychiatry :
  19. Investigational therapeutics for the treatment of progressive supranuclear palsy
    David G. Coughlin, Irene Litvan · 2022 · Expert Opinion on Investigational Drugs
  20. The duality of GSK-3β in urinary bladder cancer: Tumor suppressor and promoter roles through multiple signaling pathways
    Zufa Sabeel, Jianfeng Wang, Jian Dong, Yan Liu, Changyuan Yu, Yang Zhao · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  21. Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy
    Andrea Quattrone, Nicolai Franzmeier, Hans‐Jürgen Huppertz, Nicholas M. Seneca, Gabor C. Petzold, Annika E. Spottke, Johannes Levin, Johannes Prudlo, Emrah Düzel, the PASSPORT Study Group, the AL‐108‐231 Investigators, the Arise Investigators, the Tauros MRI Investigators, the DESCRIBE‐PSP group et al. · 2025 · Movement Disorders
  22. Emerging drugs for progressive supranuclear palsy
    Nikolaos Giagkou, María Stamelou · 2019 · Expert Opinion on Emerging Drugs
  23. Progressive supranuclear palsy treatment—A systematic review
    Samah H. Hajjar, James K. Cooper · 2016 · Basal Ganglia
  24. A Novel Neuroprotection Target With Distinct Regulation in Stroke and Alzheimer’s Disease
    Andrea Gamir-Morralla, Celia López‐Menéndez, Miguel Medina, Teresa Iglesias · 2017 · Elsevier eBooks
  25. Therapeutic options for Progressive Supranuclear Palsy including investigational drugs
    Ali Shoeibi, Irene Litvan · 2017 · Expert Opinion on Orphan Drugs
  26. Frontotemporal dementia
    Eline Wauters, Kristel Sleegers, Marc Cruts, Christine Van Broeckhoven · 2017 · Elsevier eBooks
  27. Molecular interactions and inhibition of the SARS‐CoV‐2 main protease by a thiadiazolidinone derivative
    Jacob Andrzejczyk, Katarina Jović, Logan M. Brown, Valerie G. Pascetta, Krisztina Varga, Harish Vashisth · 2022 · Proteins Structure Function and Bioinformatics
  28. Biomarkers in Randomized Clinical Trials: Magnetic Resonance Imaging
    Jennifer Louise Whitwell · 2016 · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences
  29. Tau protein aggregation: A therapeutic target for neurodegenerative diseases
    Aryan Duggal, Drishti Mahindru, Kirti Baghel, Sanjana Mehrotra, Vijay Kumar Prajapati · 2025 · Advances in protein chemistry and structural biology
  30. Progressive Supranuclear Palsy and Corticobasal Syndrome
    Nikolaus R. McFarland · 2025 · CONTINUUM Lifelong Learning in Neurology
  31. Role of GSK-3 Inhibition in Alzheimer’s Disease Therapy
    Hala Algazzawi, Jakleen Ziyad Abujamai, Asim Muhammed Alshanberi, Rukhsana Satar, Shakeel Ahmed Ansari · 2025 · Current Alzheimer Research
  32. Dementia in Parkinson’s Disease and Atypical Parkinsonism
    María Stamelou, Kailash P. Bhatia · 2014 · Springer eBooks
  33. Chemical Modulators of Protein Misfolding, Neurodegeneration and Tau
    Pierfausto Seneci · 2015 · Elsevier eBooks
  34. Screening of inhibitors of Taenia solium glycogen synthase Kinase-3β
    Li Wang, Jiagao Cheng, Shuai Wang, Xichen Zhang, Xuepeng Cai · 2017 · RSC Advances
  35. Memory formation in old age requires GSK-3β
    Riki Koike, Yuta Takaichi, Yoshiyuki Soeda, Akihiko Takashima · 2021 · Aging Brain
  36. Frontotemporal lobar degeneration
    Boram Kim, Ashley Viera-Ortiz, Jessica M. Phan, David John Irwin, Edward B. Lee · 2022 · Elsevier eBooks
  37. Diagnoses of corticobasal syndrome and corticobasal degeneration
    Takayoshi Shimohata, Ikuko Aiba, Masatoyo Nishizawa · 2016 · Rinsho Shinkeigaku
  38. Neuroprotektive Therapien bei Tauopathien
    Gesine Respondek, Lea Krey, Meret Koroni Huber, Henning Pflugrad, Florian Wegner, Günter U. Höglinger · 2021 · Der Nervenarzt
  39. Inhibition of TGF-beta signaling protects from alpha-synuclein induced toxicity
    Oscar Wing Ho Chua, Linghan Duan, Svenja Bothe, Valentin Evsyukov, Claudia Moebius, Marc Bickle, Günter U. Höglinger, Matthias Höllerhage · 2025 · Cell Death Discovery
  40. Molecular docking and simulation studies of FDA approved drugs targeting Allosteric inhibition of Glycogen synthase kinase-3β
    Karkala Sreedhara Ranganath Pai · 2026 · Jordan Journal of Pharmaceutical Sciences
  41. Tauopathies and its therapeutic interventions in Alzheimer’s disease
    Shweta Kishor Sonawane, Nagaraj Rangappa, Hariharakrishnan Chidambaram, Subashchandrabose Chinnathambi · 2026 · Advances in pharmacology
  42. Tau Phosphorylation as a Therapeutic Target in Alzheimer’s Disease
    Miguel Medina, Jesús Ávila · 2016 · Elsevier eBooks
  43. Molecular Imaging and Precision Medicine in Dementia and Movement Disorders
    Atul K. Mallik, Alexander E. Drzezga, Satoshi Minoshima · 2016 · PET Clinics
  44. Therapeutic targeting of glycogen synthase kinase-3: Strategy to address neurodegenerative diseases
    Saba Noor, Ali Raza, Md. Imtaiyaz Hassan · 2022 · Elsevier eBooks
  45. INIBIDORES DA GSK-3: UMA NOVA ESTRATÉGIA PARA A REGENERAÇÃO DENTAL
    Caroline Orejana Ghizzi Bentos, Airton Vicente Pereira · 2017 · Iniciação Científica Cesumar
  46. Morphometrische und volumetrische MRT-Auswertung
    Hans‐Jürgen Huppertz · 2018 · Clinical Epileptology
  47. Possible Treatments of Atypical Parkinsonism
    Davide Vito Moretti · 2016 · InTech eBooks
  48. Aktuelle Therapiestudien im Bereich der atypischen Parkinson Syndrome
    Kerstin Schweyer, Johannes Levin, Günter U. Höglinger · 2018 · Fortschritte der Neurologie · Psychiatrie
  49. Progressive Supranuclear Palsy
    María Stamelou, Wolfgang H. Oertel · 2017 · Springer eBooks
  50. Amyloid- and Tau-Targeted Therapies in Alzheimer’s Disease
    Alexander J. Rajic, Douglas R Galasko, Mark H. Tuszynski · 2025 · Springer eBooks
  51. Glycogen Synthase Kinase-3β: A Key Player in Alzheimer's Disease Pathogenesis and Therapeutic Targeting
    Siddhant Tripathi, Yashika Sharma, Dileep Kumar · 2025 · Current Signal Transduction Therapy
  52. Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration
    Jesús García Castro, Lawren A. VandeVrede, Michael Donohue, Lídia Vaqué‐Alcázar, Sara Rubio‐Guerra, Judit Selma‐González, Hilary W. Heuer, Alejandra Omaira Morcillo-Nieto, María Franquesa‐Mullerat, Oriol Dols‐Icardo et al. · 2026 · The Journal of Prevention of Alzheimer s Disease
  53. Identification and Characterization of New Therapeutic Targets in Acute Myeloid Leukemia
    Lina Benajiba · 2018 · theses.fr (ABES)
  54. Neurotoxicité précoce et mécanismes de neuroprotection dans des modèles poisson‐zèbre de tauopathies
    Clément Barbereau · 2020 · theses.fr (ABES)
  55. Spatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PET
    Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada et al. · 2026 · medRxiv
  56. A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
    Pepijn P.N.M. Eijsvogel, Lars M. G. Smits, Philip H. C. Kremer, Geert Jan Groeneveld · 2026 · Clinical Pharmacology & Therapeutics
  57. Neuroinflammation and Tauopathies
    Marie-Noel Zeenny, I Salame, Lynn Maatouk, Elias Akoury · 2026 · Molecular Biology Reports
  58. Spatiotemporal Tau Accumulation and its Clinical Impact on Progressive Supranuclear Palsy: Longitudinal Florzolotau ( 18F ) Positron Emission T omography
    Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada et al. · 2026 · Movement Disorders
  59. Frontotemporal lobar degeneration therapeutic development pipeline: 2026
    Alberto Benussi, Aurora Saccavini, Federica Palacino, Bradley F. Boeve, Adam L. Boxer, Edward D. Huey, Isabelle Le Ber, Raffaella Migliaccio, Chiadi U. Onyike, Olivier Piguet et al. · 2026 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  60. TGF ‐β Inhibition Attenuates Tau Accumulation and Neurodegeneration in Progressive Supranuclear Palsy Patient‐Derived Organoids
    Mariagrazia Talarico, Andrea Quattrone, Giorgia Lucia Benedetto, Raffeale Covello, Maurizio Martini, Valeria Zuccalà, Giovanni Cuda, Elvira Immacolata Parrotta, Aldo Quattrone · 2026 · Movement Disorders
  61. BindingDB Entry 50000052: Subtly Modulating Glycogen Synthase Kinase 3β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases.
    BindingDB · 2019 · UC San Diego
  62. BindingDB Entry 50017353: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
    BindingDB · 2023 · UC San Diego
  63. Genetics of Atypical Parkinsonism
    María Stamelou, Kailash P. Bhatia · 2015 · Springer eBooks